(Q64449267)

English

Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy

scientific article published on 01 March 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Gopal K Bajaj

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Zhe Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Elizabeth Garrett-Mayer

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Renee Drew

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Victoria Sinibaldi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Roberto Pili

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Samuel R Denmeade

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Michael A Carducci

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Mario A Eisenberger

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Theodore L DeWeese

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

0 references

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

69

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

526-531

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Signal transduction by the platelet-derived growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

The biology of platelet-derived growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Role of tyrosine kinase and membrane-spanning domains in signal transduction by the platelet-derived growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Endothelium-derived factors as paracrine mediators of prostate cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Platelet-derived growth factor induces proliferation of hyperplastic human prostatic stromal cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Mechanism of action and in vivo role of platelet-derived growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Definitions of biochemical failure in prostate cancer following radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2006.12.006

7 January 2021

Identifiers

10.1016/J.UROLOGY.2006.12.006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17382158%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64449267&oldid=2089130071"